What happened
PharmaResearch filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$100M (+25% year on year), operating profit of US$39.4M (+28.1% year on year) and net income of US$33.5M (+35.3% year on year).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$100M |
|---|---|
| Revenue vs a year earlier | +25% |
| Operating profit | US$39.4M |
| Net income | US$33.5M |
| Period | Q1 2026 (consolidated) |
| Filed | 2026-05-08, Operating results (consolidated) (preliminary) (fair disclosure) |
| Source | DART rcept 20260508900237 → open original filing |
Source: DART. Information only, not investment advice.